Health-related quality of life after IMRT or IMRT+ HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial. This is an ASCO Meeting Abstract from the ...
Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
Recent advancements in deep learning have significantly transformed the field of nuclear medicine, specifically in the detection and analysis of bone metastases via scintigraphy. By leveraging ...
Reston, VA—A new study has determined that approximately three percent of all bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality. Published ...
The U.S. FDA granted 510(k) clearance to Lantheus Holdings Inc.'s artificial intelligence (AI)-enhanced automated bone scan index (aBSI) product for prostate cancer on GE Healthcare's Xeleris platform ...
Effect of tissue ischemia on prostatic androgen levels. Background: Quantification of bone metastases in the skeleton expressed as Bone Scan Index (BSI) and location of these are prognostic factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results